Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures can feel like a maze. Enliven Therapeutics’ pipeline updates, cash-runway tables, and trial safety data sprawl across hundreds of pages. If you have searched for “understanding Enliven Therapeutics SEC documents with AI” or “Enliven Therapeutics SEC filings explained simply,” you are not alone—investors regularly struggle to locate the data that drives this precision-oncology stock.
Stock Titan solves that problem. Our AI-powered summaries dissect every Enliven Therapeutics quarterly earnings report 10-Q filing, annual report, and 8-K the moment they appear on EDGAR. Need alerts on Enliven Therapeutics Form 4 insider transactions real-time? We flag each entry, spotlighting notable Enliven Therapeutics insider trading Form 4 transactions alongside context such as share price, option exercise, and historical patterns. Side-by-side comparisons, cash-burn ratios, and dilution math are pulled automatically, turning an Enliven Therapeutics earnings report filing analysis into a five-minute read.
The details that matter most in early-stage biotech rarely sit on page one. Our platform highlights milestone payment clauses, going-concern language, and patent timelines inside an Enliven Therapeutics annual report 10-K simplified synopsis. You can drill into option grants through every Enliven Therapeutics executive stock transactions Form 4, review board pay with the Enliven Therapeutics proxy statement executive compensation section, and receive push notifications when an Enliven Therapeutics 8-K material events explained alert covers trial data or FDA designations. All filings update in real time, backed by clean, plain-English AI commentary that lets you focus on decisions, not document hunting.
Enliven Therapeutics (ELVN) filed an 8‑K/A to amend its November 12, 2025 current report, correcting the press release attached as Exhibit 99.1.
The corrected release covers financial results for the quarter ended September 30, 2025. Information in Items 2.02 and 9.01 (including Exhibit 99.1) is furnished, not filed, under the Exchange Act.
Enliven Therapeutics (ELVN) disclosed insider transactions by its Chief Operating Officer. On 11/07/2025, the reporting person executed sales of 6,054 shares at a weighted average price of $17.3503 and 613 shares at a weighted average price of $17.9371, effected under a Rule 10b5-1 trading plan adopted on September 30, 2024.
The trades were completed in multiple transactions within disclosed price ranges, and the shares are held indirectly by The Patel / Dong Family Trust, for which the reporting person serves as trustee. Following the reported sales, beneficial ownership stood at 269,974 shares held indirectly.
Enliven Therapeutics (ELVN) reported Q3 2025 results. Operating expenses were $25.1 million, driven by research and development of $18.2 million and general and administrative of $6.9 million. The company recorded a net loss of $20.1 million, or $0.32 per share, compared with a net loss of $23.2 million a year ago.
Cash, cash equivalents and marketable securities totaled $477.6 million as of September 30, 2025, supported by a June underwritten public offering of 9,920,987 shares and pre-funded warrants to purchase 1,780,263 shares, delivering $230.0 million gross proceeds. Net cash used in operating activities for the nine months was $54.5 million. Shares outstanding were 59,347,317 as of October 31, 2025.
The company filed an automatic shelf on August 13, 2025 and added an at-the-market program covering up to $200.0 million of common stock; no sales occurred under the program during the period. Management states existing liquidity will fund planned operating expenses and capital requirements for at least 12 months from issuance.
Enliven Therapeutics (ELVN)Exhibit 99.1 and was issued on November 12, 2025.
The company notes that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated.
Enliven Therapeutics (ELVN) reported an insider transaction by its Chief Scientific Officer on Form 4. The filing shows a sale of 12,500 shares of common stock on October 20, 2025 at a weighted average price of $22.082, executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following the sale, the reporting person beneficially owned 915,188 shares, held indirectly through The Lyssikatos Revocable Trust dated 12/15/2011.
The transaction price ranged from $21.285 to $22.36, with full trade details available upon request.
Enliven Therapeutics (ELVN) reported an insider transaction: its President & CEO and Director sold 12,500 shares of Common Stock on 10/17/2025 at a $21.3323 weighted average price. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
The transaction was executed in multiple trades within a price range of $21.1303 to $21.88. Following the sale, the reporting person beneficially owned 902,892 shares, held indirectly by The Kintz & Egan Trust Dated March 30, 2019.
Anish Patel, Chief Operating Officer of Enliven Therapeutics (ELVN), sold 6,667 shares of common stock on
Enliven Therapeutics insider sale by Chief Scientific Officer
Joseph P. Lyssikatos, Enliven Therapeutics' Chief Scientific Officer, reported a sale of 4,000 shares of the company's common stock on 09/26/2025 at a weighted average price of $20.2513 per share. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/2024. After the reported disposition, the reporting person beneficially owns 927,688 shares indirectly through The Lyssikatos Revocable Trust dated 12/15/2011, for which he serves as trustee. The Form 4 was signed by power of attorney on 09/30/2025.
Samuel Kintz, President, CEO and a director of Enliven Therapeutics, Inc. (ELVN), reported a sale of 3,700 shares of the company's common stock on 09/26/2025. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024, and executed in multiple trades at prices ranging from $20.00 to $20.27, with a weighted average price of $20.0615. After the reported disposition, the reporting person beneficially owns 915,392 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee. The Form 4 is signed by a power of attorney on behalf of the reporting person.
Enliven Therapeutics (ELVN) filing a Form 144 notifies a proposed brokered sale of 4,500 common shares through Jefferies with an aggregate market value of $90,045, planned for 09/29/2025. The shares were acquired as stock options on 08/09/2022 from the company. The filing shows 59,000,000 shares outstanding for the issuer and discloses prior insider sales of 7,500 shares during the past three months with reported gross proceeds totaling roughly $156,197.50. The filer attests there is no undisclosed material adverse information and the transaction will be executed through a broker.
FAQ
What is the current stock price of Enliven Therapeutics (ELVN)?
What is the market cap of Enliven Therapeutics (ELVN)?
